These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23333701)

  • 21. Synthesis and biological evaluation of the binding of dopamine D2/D3 receptor agonist, (R,S)-5-hydroxy-2-(N-propyl-N-(5'-(18)F-fluoropentyl)aminotetralin ((18)F-5-OH-FPPAT) in rodents and nonhuman primates.
    Shi B; Narayanan TK; Christian BT; Chattopadhyay S; Mukherjee J
    Nucl Med Biol; 2004 Apr; 31(3):303-11. PubMed ID: 15028242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.
    Graff-Guerrero A; Willeit M; Ginovart N; Mamo D; Mizrahi R; Rusjan P; Vitcu I; Seeman P; Wilson AA; Kapur S
    Hum Brain Mapp; 2008 Apr; 29(4):400-10. PubMed ID: 17497628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.
    Matuskey D; Worhunksy P; Correa E; Pittman B; Gallezot JD; Nabulsi N; Ropchan J; Sreeram V; Gudepu R; Gaiser E; Cosgrove K; Ding YS; Potenza MN; Huang Y; Malison RT; Carson RE
    Neuroimage; 2016 Apr; 130():241-247. PubMed ID: 26876475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.
    Caravaggio F; Kegeles LS; Wilson AA; Remington G; Borlido C; Mamo DC; Graff-Guerrero A
    Synapse; 2016 Nov; 70(11):453-60. PubMed ID: 27341789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study.
    Nakajima S; Caravaggio F; Boileau I; Chung JK; Plitman E; Gerretsen P; Wilson AA; Houle S; Mamo DC; Graff-Guerrero A
    J Cereb Blood Flow Metab; 2015 Nov; 35(11):1812-8. PubMed ID: 26058690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs.
    Cumming P; Gillings NM; Jensen SB; Bjarkam C; Gjedde A
    Nucl Med Biol; 2003 Jul; 30(5):547-53. PubMed ID: 12831994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey.
    Finnema SJ; Seneca N; Farde L; Shchukin E; Sóvágó J; Gulyás B; Wikström HV; Innis RB; Neumeyer JL; Halldin C
    Nucl Med Biol; 2005 May; 32(4):353-60. PubMed ID: 15878504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.
    de Vries EF; Kortekaas R; van Waarde A; Dijkstra D; Elsinga PH; Vaalburg W
    J Nucl Med; 2005 Aug; 46(8):1384-92. PubMed ID: 16085598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO.
    Willeit M; Ginovart N; Kapur S; Houle S; Hussey D; Seeman P; Wilson AA
    Biol Psychiatry; 2006 Mar; 59(5):389-94. PubMed ID: 16373068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release.
    McCormick PN; Ginovart N; Wilson AA
    Mol Imaging Biol; 2011 Aug; 13(4):737-46. PubMed ID: 20680481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain.
    Ginovart N; Willeit M; Rusjan P; Graff A; Bloomfield PM; Houle S; Kapur S; Wilson AA
    J Cereb Blood Flow Metab; 2007 Apr; 27(4):857-71. PubMed ID: 17033687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
    Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.
    Takahata K; Ito H; Takano H; Arakawa R; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Nogami T; Suzuki M; Nagashima T; Shimada H; Kato M; Mimura M; Suhara T
    Psychopharmacology (Berl); 2012 Jul; 222(1):165-72. PubMed ID: 22237854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹⁸F]fallypride and [¹⁸F]desmethoxyfallypride.
    Constantinescu CC; Coleman RA; Pan ML; Mukherjee J
    Synapse; 2011 Aug; 65(8):778-87. PubMed ID: 21218455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
    Tateno A; Sakayori T; Kim WC; Honjo K; Nakayama H; Arakawa R; Okubo Y
    Int J Neuropsychopharmacol; 2018 Jun; 21(6):522-527. PubMed ID: 29346639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.
    Suridjan I; Rusjan P; Addington J; Wilson AA; Houle S; Mizrahi R
    J Psychiatry Neurosci; 2013 Mar; 38(2):98-106. PubMed ID: 23010256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
    Graff-Guerrero A; Redden L; Abi-Saab W; Katz DA; Houle S; Barsoum P; Bhathena A; Palaparthy R; Saltarelli MD; Kapur S
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):273-87. PubMed ID: 19751545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.
    McCormick PN; Kapur S; Seeman P; Wilson AA
    Nucl Med Biol; 2008 Jan; 35(1):11-7. PubMed ID: 18158938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Kappa Opioid Receptor Agonist as Improved PET Radiotracer: Development and in Vivo Evaluation.
    Li S; Zheng MQ; Naganawa M; Gao H; Pracitto R; Shirali A; Lin SF; Teng JK; Ropchan J; Huang Y
    Mol Pharm; 2019 Apr; 16(4):1523-1531. PubMed ID: 30726092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.